PSE
20.4.2021 13:49:12 CEST | Business Wire | Press release
Process Systems Enterprise (PSE), a Siemens business, today released its rebranded gPROMS Process advanced process modelling environment.
Formerly known as gPROMS ProcessBuilder, gPROMS Process 2.0 is the first major release since PSE was acquired by Siemens. Eckard Eberle, CEO of Siemens Digital Industries Process Automation division, says “the significantly enhanced capabilities and functionality you see in this release reflect the substantial investment Siemens is making into product development within PSE to provide the process industries with a new generation of digital tools.”
Costas Pantelides, PSE CEO and architect of the gPROMS platform, says “The name change signifies a break with the past. Until now, ProcessBuilder has been an environment for sophisticated users who are typically running high-value, complex optimizations. This is the first release in a major, multi-year development programme that will bring the cutting-edge capabilities of the gPROMS platform to users across process organisations”.
The release contains significant new model library content, including a new polyolefins library to support online nonlinear control applications for polymers such as LDPE and HDPE; an advanced model library for electrochemical reactors to support the optimization of clean energy and hydrogen systems; a data-driven model library for hybrid modelling combining data-driven elements with first-principles models; new batch distillation and decanter models for specialty chemicals; enhancements to the multistream heat exchanger for LNG and cryogenic process optimization and to PSE’s industry-leading catalytic reactors model library; and a unique new cyclic steady-state solver to speed up modelling of adsorption processes.
gPROMS Process includes an all-new integral gPROMS Properties package containing all industry-standard thermodynamic models plus PSE’s industry-leading SAFT-γ Mie, which allows accurate prediction of physical properties and phase behaviour with minimal experimental data. “We aim to provide the world’s leading materials modelling capability within a process simulator”, says Pantelides. “covering strongly associating, polymer and active pharmaceutical ingredient systems within a single properties package”.
gPROMS Process also supports the automatic generation of fast-solving surrogate models, technology already extensively proven on large-scale, multi-site optimization projects. A new interface to Siemens’ STAR-CCM+ simplifies combining process and CFD hydrodynamic models for detailed equipment design. Support for the gPROMS Web Applications Platform (gWAP) makes it easy to supply models to users across the organisation via web interfaces.
gPROMS Process is unique among process simulation tools in that it was designed from the start to support the entire process lifecycle, from R&D to operations. Its comprehensive digital design capability makes it possible to explore the process decision space rapidly and effectively, and determine optimal values for multiple design variables simultaneously to arrive at truly optimized designs in the minimum time. gPROMS Process models can be exported for implementation online within the gPROMS Digital Applications Platform (gDAP), for real-time monitoring, soft-sensing and real-time optimization applications coupled with plant data.
About: www.psenterprise.com/news/pressroom
View source version on businesswire.com: https://www.businesswire.com/news/home/20210420005688/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NTT DOCOMO BUSINESS and Chile’s State-owned Copper Company CODELCO Launch a Study and Proof of Concept Aimed at Improving the Efficiency of Remote Copper Mine Operations Using IOWN® APN6.8.2026 06:30:00 CEST | Press release
NTT DOCOMO BUSINESS, Inc. (formerly NTT Communications Corporation) has launched a study and proof of concept jointly with Corporación Nacional del Cobre de Chile (CODELCO) to progress remote operations at CODELCO’s copper mines using an IOWN® All-Photonics Network (APN).1 This initiative is part of a research project commissioned by Japan’s Ministry of Internal Affairs and Communications.2 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806845222/en/ Conceptual Diagram of the Demonstration To address operational challenges faced by CODELCO’s copper mines, the initiative will connect a copper mine and a remote operations center—approximately 1,500 km apart—via an IOWN APN. It will assess the feasibility of remotely operating heavy machinery using high-capacity, low-latency communication links, enhancing monitoring operations through high-definition video, and implementing a remote operations model. 1. Background Chile is o
FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom